The mechanism by which eukaryotic genes are activated is inextricably linked with the packaging of DNA into chromatin. Coactivator complexes with histone-modifying activities play essential roles in this process by altering chromatin dynamics and interactions. Although there have been major advances in a molecular understanding many of the key macromolecular machines involved in eukaryotic transcription, progress in understanding coactivator function has lagged due to limited structural information on these large complexes and their interactions with chromatin. The SAGA coactivator is a 19-protein complex that has served as a paradigm for understanding the regulation of eukaryotic transcription and the connection between histone modifications and gene activation. SAGA deubiquitinates histone H2B, acetylates histone H3, and plays multiple roles in promoting transcription initiation and elongation. We have made substantial progress in our structural and biochemical studies of the SAGA deubiquitinating subcomplex and its interactions with ubiquitinated nucleosomes, as well as in our studies of Ubp10, a second H2B deubiquitinating enzyme, and of the interplay between histone chaperone activity and H2B deubiquitination. We will extend our studies to the full SAGA complex, determining the structure of SAGA bound to nucleosomes containing the relevant ubiquitin and methyl-lysine modifications by the method of cryo-electron microscopy. The resulting insights will reveal how the SAGA complex interfaces with the other components of the transcriptional machinery and will shed light on the mechanism by which histone ubiquitination, acetylation and methylation are manipulated to facilitate transcription through chromatin templates.
Disregulation of SAGA is implicated in human disease; overexpression of USP22, human homologue yeast Ubp8, is a signature of cancers for which there is no effective treatment while ATXN7, homologue of yeast Sgf73, is the effected protein in glutamine expansion disease, Spinocerebellar Ataxia Type 7. Insights from our structural studies of the yeast SAGA complex can be exploited to devise new therapies targeting human SAGA.
Showing the most recent 10 out of 20 publications